Although regulators are increasingly mandating pharmaceutical risk-minimization programs, insufficient attention has been given to maximizing or measuring their effectiveness as public health interventions.

Application of evidence- and theory-based approaches from the field of implementation science can increase the likelihood of program effectiveness by guiding what should be done to produce successful outcomes and what types of questions should be asked to assess program success.